(Q42980741)

English

Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin

scientific article published on October 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin (English)

1 reference

Europe PubMed Central

12 November 2017

1 reference

based on heuristic

inferred from title

Adrian M. Di Bisceglie

5

object named as

Adrian M Di Bisceglie

1 reference

Europe PubMed Central

12 November 2017

author name string

Michael W Fried

1

1 reference

Europe PubMed Central

12 November 2017

Donald M Jensen

2

1 reference

Europe PubMed Central

12 November 2017

Maribel Rodriguez-Torres

3

1 reference

Europe PubMed Central

12 November 2017

Lisa M Nyberg

4

1 reference

Europe PubMed Central

12 November 2017

Timothy R Morgan

6

1 reference

Europe PubMed Central

12 November 2017

Paul J Pockros

7

1 reference

Europe PubMed Central

12 November 2017

Amy Lin

8

1 reference

Europe PubMed Central

12 November 2017

Lisa Cupelli

9

1 reference

Europe PubMed Central

12 November 2017

Frank Duff

10

1 reference

Europe PubMed Central

12 November 2017

Ka Wang

11

1 reference

Europe PubMed Central

12 November 2017

David R Nelson

12

1 reference

Europe PubMed Central

12 November 2017

language of work or name

0 references

publication date

1 October 2008

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

48

1 reference

Europe PubMed Central

12 November 2017

4

1 reference

Europe PubMed Central

12 November 2017

1033-1043

1 reference

Europe PubMed Central

12 November 2017

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Race, insulin resistance and hepatic steatosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD).

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Optimizing treatment regimens in hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Antiviral action of ribavirin in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

21 January 2018

Hepatitis C and steatosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22448

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.22448

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42980741&oldid=1975630209"